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A B S T R A C T
The term “hyperthyroidism” indicates a condition due to an exaggerate production of thyroid hormone; the most
frequent cause is Graves’ disease (GD).
We review cytokines and chemokines in hyperthyroidism, with a special focus in GD.
In GD, recruited Th1 lymphocytes are responsible for enhanced IFN-γ and TNF-α production, which in turn
stimulates Th1 chemokines release from thyrocytes, initiating and perpetuating the autoimmune process.
Circulating levels of these chemokines are associated with the active phase of GD.
Additional studies are necessary to investigate whether Th1 chemokines could be a novel therapeutic target in
this disease.
Introduction
Hyperthyroidism
The terms “hyperthyroidism” and “thyrotoxicosis” are usually used
in an interchangeable manner [1], but the ﬁrst is a condition that oc-
curs due to an exaggerate production of thyroid hormone by the thyroid
[2], while the second is a condition occurring owing to excessive
thyroid hormone by any cause, and for this reason it includes hy-
perthyroidism [2]. Diﬀerent signs and symptoms exist: sleeping pro-
blems, irritability, heat intolerance, muscle weakness, hand tremor, a
fast heartbeat, diarrhea, weight loss, and enlargement of the thyroid for
Graves’ disease (GD) and toxic multinodular goiter (TMN) (these signs
and symptoms are lower in old people and in pregnancy) [3]. “Thyroid
storm” is an unfrequent complication causing worsening symptoms,
high temperature and confusion, and often leading to death [4].
In the United States, approximately 1.2% of the population is af-
fected by hyperthyroidism [1]. The onset is frequently between 20 and
50 years of age, and more often in women, for GD [3,4], while in pa-
tients with TMN, or toxic adenoma, the disease is more frequent in
people over the age of 50 years [3]. The diagnosis of hyperthyroidism is
based on signs and symptoms and should be conﬁrmed by blood tests
[3], a low thyroid stimulating hormone (TSH), and raised triiodothyr-
onine (T3) or thyroxine (T4) [3]. Moreover, to deﬁne the cause,
radioactive iodine uptake by the thyroid and subsequent thyroid scan,
ultrasonography, and thyroid-stimulating immunoglobulins (TSI) can
be of help [3].
In the United States, approximately 50–80% of the cases of hy-
perthyroidism is caused by GD [3,5]. Other causes are inﬂammation of
the thyroid, multinodular goiter, toxic adenoma, an iodine excess, and
the exaggerated administration of synthetic thyroid hormone [3,4].
Pituitary adenoma is a less frequent cause [3]. A complicated interac-
tion of genetic, environmental and endogenous factors are at the basis
of GD, that is a systemic autoimmune disorder, aﬀecting thyroid and
orbital connective tissue. The determinant role of the autoimmune re-
sponse in the development of GD has been shown, as well as the pa-
thogenetic role covered by thyroid stimulating autoantibodies [6,7].
Genetic factors are considered to be involved in the development of
autoimmune thyroid diseases (AITDs) for approximately 70% [8]. The
genes encoding for TSH receptor, thyroglobulin, CD40, cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4), protein tyrosine phospha-
tase-22 (PTPN 22), CD25, and human leukocyte antigens (HLA) con-
tribute to the pathogenesis of GD [9]. GD has been considered a HLA
class II-associated disease. For example, the DR3 allele has been asso-
ciated with GD and, slightly, Hashimoto thyroiditis (HT) [10]. In par-
ticular, the ‘‘DR3 haplotype’’ (i.e., DQA1*0501, DQB1*02, DRB1*03), is
predisposing to GD, owing to the high degree of linkage disequilibrium
among these DQA1, DQB1, and DRB1 loci, while the DR7 haplotype
(i.e., DQA1*0201, DQB1*0302, DRB1*07 or DQA1*0201, DQB1*02,
DRB1*07) is considered protective [11]. When DRB1*07 and DRB1*03
are present, the ﬁrst seems to counteract the susceptibility to GD given
by the second [12].
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Environmental factors contribute approximately for 30% to the
development of the disease.
One environmental factor at the basis of GD is stress, that has long
been considered a potential trigger for GD [11,13]. Infectious, physical
stressful, and psychological events may induce the onset and, partly,
the recurrences of hyperthyroidism in GD [14].
A study conducted serological HLA typing in 58 Caucasian patients
with stress-related GD and in 130 matched healthy controls, and
genomic HLA typing in 20/58 patients and in all controls [11]. Five
HLA alleles and 3 loci were more common in patients compared to
healthy controls: B8, Cw7, C*07, C*17, DR3, DR4, DRB1*04, and DQ2,
while B14 was less frequent in patients than in controls. The Authors
concluded that in GD patients with stress-triggered hyperthyroidism,
HLA typing could be useful to predict the outcome of the disease [11].
Smoking is another well-established risk factor for GD. The odds
ratio (OR) for Graves’ hyperthyroidism is 3.30 (95% conﬁdence interval
(CI) = 2.09–5.22) in current smokers in comparison to never smokers
[15,16].
The role of diﬀerent viruses in the development of GD has been also
investigated [17,18].
From an immune-pathogenetic point of view, GD is a predominantly
Th1 cytokine disease, even if hyperthyroidism is due to the presence of
thyroid-stimulating antibodies (TSAbs). In fact, Th1 cytokines and
chemokines are very important in its pathogenesis [19,20].
During the course of GD, T-helper cell 17 (Th17)/Treg cell in-
ﬁltration, Th1/Th2 cytokine and chemokine production, and the pre-
sence of subtypes of immunoglobulins are some of the inﬂammatory
events occurring.
Diﬀerent treatment options are known, according to the cause and
severity of the disease: medications, radioiodine therapy, and thyroid
surgery [3]. Medications are beta blockers, that are able to control the
symptoms, and anti-thyroid medications, such as methimazole (MMI)
[3]. In case of opting for radioiodine therapy, the patient receives io-
dine-131 by mouth, that is absorbed into the gut, and then transported
and concentrated into the thyroid, destroying it upon weeks to months,
leading to hypothyroidism, that is then treated with synthetic thyroid
hormone [3]. Surgery is used to remove the thyroid, in particular in
presence of a large thyroid volume, or cancer [3].
Cytokines and chemokines
Cytokines are small proteins (∼5–20 kDa), important in cell sig-
naling. These peptides cannot cross the lipid bilayer and for this reason
cannot simply enter the cytoplasm. Cytokines are involved in autocrine,
paracrine and endocrine signaling as immunomodulating agents. Even
if some overlap in the terminology exists, cytokines include interleukins
(IL), chemokines, interferons (IFNs), tumor necrosis factors (TNFs), and
lymphokines, but not growth factors or hormones. They are important
in physiology as well as in certain diseases, in particular in host re-
sponses to infection, immune responses, inﬂammation, cancer, trauma,
reproduction, and sepsis. Cytokines act through receptors, and mod-
ulate the balance between humoral and cell-based immune responses;
they regulate the maturation, growth, and responsiveness of particular
cell populations. Some cytokines enhance, or inhibit, the action of other
cytokines. Cytokines are produced by various types of cells, as immune
cells (macrophages, mast cells, B lymphocytes, and T lymphocytes), and
endothelial cells, ﬁbroblasts, and various stromal cells [21,22].
Chemokines (chemotactic cytokines) are a family of small cytokines,
or signaling proteins secreted by cells, whose name derives from their
ability to induce directed chemotaxis in nearby responsive cells.
Chemokines are all about 8–10 kDa in mass and have 4 cysteine re-
sidues in conserved positions, that determine their 3-dimensional
shape. Some chemokines are considered homeostatic and they control
the migration of cells during normal processes of tissue maintenance, or
development; while others are considered pro-inﬂammatory and can be
induced during an immune response to recruit cells of the immune
system to a site of infection, or inﬂammation. Chemokines have been
classiﬁed into 4 principal subfamilies: CXC, CC, CX3C and XC. All of
them exert their biological eﬀects by interacting with G protein-linked
transmembrane receptors (called chemokine receptors), selectively
present on the surfaces of their target cells [23]. The chemokine re-
ceptor (CXCR)3 belongs to the family of C-X-C chemokine receptors,
with the 2 isoforms CXCR3-A and CXCR3-B, and binds the Th1 de-
pendent chemokines, IFN-γ-inducible protein 10 (IP-10)/chemokine
ligand 10 (C-X-C motif) (CXCL)10, monokine induced by IFN-γ (MIG)/
CXCL9 and IFN-inducible T-cell α chemoattractant (I-TAC)/CXCL11
[24]. CXCR3 is expressed by diﬀerent cells, as activated T lymphocytes,
Natural Killer, some epithelial and endothelial cells, and it is highly
expressed on Th1 cells, such as the chemokine receptor (C–C motif)
(CCR)5. Th1 cells are attracted in the tissue by CXCL9, CXCL10 and
CXCL11 chemokines that are released by the cells into the inﬂamed
tissues. Hence, this mechanism underlined the central role played by
both CXCR3 and its ligands in the recruitment of inﬂammatory cells
[25,26].
The Th1 lymphocytes recruited in the inﬂamed tissue increase the
IFN-γ and TNF-α production, that leads to a Th1 chemokines secretion
by several cells, creating an ampliﬁcation feedback loop [27,28]. The
high level of Th1 chemokines in peripheral ﬂuids can be considered as a
marker for the host immune response [27,28]. High serum and tissue
levels of Th1 chemokines have been reported in speciﬁc autoimmune
diseases, as: autoimmune thyroiditis (AT) [20,29–36], GD [37], Graves’
ophthalmopathy [38,39], type 1 diabetes [40], or systemic rheumato-
logical disorders, like SLE [41], rheumatoid arthritis [42], systemic
sclerosis [43], sarcoidosis [44], psoriasis or psoriatic arthritis [45,46],
HCV-related cryoglobulinemia [47–49], other HCV-immune-mediated
disorders [31,50,51], other disorders, and also in cancers [16,52].
Here, we review cytokines and chemokines in hyperthyroidism,
with a special focus in GD.
Hyperthyroidism and cytokines
Diﬀerent circulating cytokines are increased in autoimmune (as IL-6
and IL-18) [53–55] as well as non-autoimmune hyperthyroidism (as IL-
6, TNF-α, and IL-8) [56–58], indicating that this could result from the
chronic eﬀects of thyroid hormone excess, rather than from the ac-
companying autoimmune, inﬂammatory condition present in GD. The
matter is complicated, and conclusions should be drawn carefully, as
several demographic, clinical and therapeutical variables, which have
not always been cautiously investigated, could lead to biased results.
For instance, very few studies establishing the importance of serum
cytokines in hyperthyroidism have taken into account the role of age,
that seems to be a determinant variable, signiﬁcantly and directly
correlated with several cytokines, and particularly CXCL10, as earlier
reported [59]. Hence, it should be considered that toxic nodular goiter
(TNG) patients are usually older than GD patients. Furthermore, serum
thyroid hormones, whose levels are generally higher in GD, and the use
of corticosteroid therapy (used in GD patients with ophthalmopathy),
should be considered when comparing serum cytokines in GD and TNG
patients.
Th1 chemokines in GD (Table 1)
In GD, unlike CXCL10 which was observed either in inﬁltrating
inﬂammatory and endothelial cells and thyrocytes, CXCR3 receptor
turned out to be more expressed only in the ﬁrst two types of cells [60].
Another study showed that in GD, the recruitment of inﬂammatory cells
and the following ampliﬁcation of inﬂammation are dependent on
CXCR3-binding chemokine CXCL10, and suggested that at the begin-
ning of GD the recruitment of CXCR3-expressing Th1 cells can be
caused by the production of this chemokine by resident follicular epi-
thelial cells [61].
Higher circulating CXCL10 levels have been observed in GD patients
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in comparison to the controls (matched by age and sex) [62]. Diﬀer-
ently from GD patients with untreated hyperthyroidism, subjects with
euthyroid or hyperthyroid GD under MMI treatment had lower serum
CXCL10 levels; meanwhile these levels were higher in hyperthyroid GD
patients compared to hypothyroid or euthyroid GD ones [37]. Serum
CXCL10 levels turned out to be similar both in untreated patients with
relapsed hyperthyroidism who previously took MMI, and in recently
diagnosed untreated hyperthyroid GD subjects. These results showed
that either in relapsing hyperthyroid patients, or in the newly diag-
nosed ones, the active phase of GD is associated with elevated serum
CXCL10 levels [37].
Serum levels of CCL2, CCL5, CXCL9 and CXCL10 in patients with
GD, HT and nontoxic nodular thyroid disease (NNT) have been assessed
in a further study [63]. Despite CCL2 and CXCL9, whose concentrations
were similar in patients with AITD and NNT, CCL5 was substantially
higher in GD patients than in the HT or NNT ones. Conversely, CXCL10
levels were lower in patients with GD, with a diﬀerence that reach the
signiﬁcativity only when compared to HT subjects. Of note, diﬀerent
statistically signiﬁcant levels of CXCL9 were observed in GD patients
who relapsed or went into remission. These ﬁndings suggested that the
distinct immune responses in GD and HT can be related to the diﬀerent
expression patterns of chemokines [63].
Other studies assessed the action of peroxisome proliferator-acti-
vated receptor (PPAR)-γ and of the IFN-γ and TNF-α stimulation on the
CXCL10, CXCL9, CXCL11 release, in primary cells of GD thyrocytes
[62,64,65]. Basally, the secretion of these chemokines was absent, and
they were dose-dependently released treating cells with IFN-γ, while
TNF-α alone had no eﬀect. The treatment with TNF-α+ IFN-γ had a
synergistic eﬀect on the CXCL10, CXCL9 and CXCL11 secretion. The co-
treatment with the PPAR-γ agonist, rosiglitazone, or pioglitazone sup-
pressed this eﬀect in a dose-dependent manner. These results demon-
strated that thyrocytes from patients with GD under the cytokines sti-
mulation participate to the self-protraction of inﬂammation by
releasing CXCL9, CXCL10, and CXCL11, and PPAR-γ inhibited this ef-
fect. Among the CXC chemokines, the CXCL9 leading role was sug-
gested by its high response to the IFN-γ+TNF-α -stimulation [64].
The eﬀect of PPAR-α activation on CXCL10, CXCL9 and CXCL11
chemokines in general, or on the secretion of these chemokines in
thyrocytes has been evaluated by other studies [38,66]. The presence of
PPAR-α and PPAR-γ in GD and control cells in primary culture has been
shown by real-time reverse transcription-polymerase chain reaction
(RT-PCR). The role of PPAR-α and PPAR-γ activation on chemokines
secretion has been also evaluated after the treatment of GD and control
cells with IFN-γ and TNF-α. A strong dose-dependent inhibition on the
cytokines-stimulated secretion of CXCL11, CXCL10, and CXCL9 by
PPAR-α-agonists has been observed in both primary culture cells. The
eﬀect of PPAR-α-agonists was higher on the release of CXCL9 (85% of
inhibition with ciproﬁbrate, 90% with fenoﬁbrate). The compounds
had a diﬀerent potency for each chemokine; for instance, the inhibition
exerted by gemﬁbrozil on CXCL11 was of 55%, while it exerted a lower
inhibition on CXCL9 secretion, of 40%. In thyrocytes, the inhibition of
CXCL10, CXCL9 and CXCL11 secretion was greater with PPAR-α ago-
nists than with PPAR-γ agonists. These ﬁndings suggested that the
immune response in thyroid may be modulated by PPAR-α [38,66].
In another study [67], CXCL9 and CXCL11 levels were measured in
the sera of 91 GD patients, 91 AT, 34 nontoxic multinodular goiters
(MNGs), 31 TNGs, and 91 healthy subjects (matched by sex and age).
The mean chemokines levels found in GD, controls, euthyroid AT, MNG,
or TNG were the following: CXCL9: 274 ± 265, 76 ± 33, 132 ± 78,
87 ± 48, and 112 ± 56 pg/mL; CXCL11: 140 ± 92, 64 ± 20,
108 ± 48, 76 ± 33, 91 ± 41 pg/mL, respectively (p < 0.05,
ANOVA). These levels were more elevated in GD patients with respect
to those in other subjects. Chemokines levels were signiﬁcantly higher
in hyperthyroid GD patients than hypothyroid, or euthyroid ones.
Furthermore, these levels were higher in GD patients with untreated
hyperthyroidism than euthyroid, or hyperthyroid, GD subjects treated
Table 1
Role of citokines/chemokines in Graves’ disease (GD) pathogenesis: results of in vitro and in vivo studies.
Cytokines In vivo studies In vitro studies
CXCL10 - Important role in the recruitment of inﬂammatory cells and in the
ampliﬁcation of inﬂammation in AITDs [61].
- High serum levels in relapsing hyperthyroid GD patients, and in
the newly diagnosed ones [37].
- High circulating serum levels in GD patients [62].
- Diﬀerent expression patterns of chemokines in the various
thyroid diseases [63].
- Thyroid follicular cells represent an important source of CXCL10, which can mediate the
recruitment of activated CXCR3+ lymphocytes to the thyroid in AITDs [60].
- Under the Th1 cytokine IFN-γ stimulation, thyrocytes participate to the induction and
perpetuation of inﬂammation by releasing CXCL10; PPAR-γ inhibited this eﬀect [64].
- PPAR-α activation had an inhibitory role on CXCL10 secretion by thyroid cells [38,66].
CXCL9 - Important role in the recruitment of inﬂammatory cells and in the
ampliﬁcation of inﬂammation in AITDs [61].
- Diﬀerent expression patterns of chemokines in the various
thyroid diseases [63].
- Association of the serum chemokines levels with the active phase
of GD [67].
- Association between the intractability of GD and the MIG
rs2276886 AG genotype [68].
- Thyroid follicular cells represent an important source of CXCL9, which can mediate the
recruitment of activated CXCR3+ lymphocytes to the thyroid in AITDs [60].
- Under the Th1 cytokine IFN-γ stimulation, thyrocytes participate to the induction and
perpetuation of inﬂammation by releasing CXCL9; PPAR-γ inhibited this eﬀect [64].
- PPAR-α activation had an inhibitory role on CXCL9 secretion by thyroid cells [38,66].
CXCL11 - Association of the serum chemokines levels with the active phase
of GD [67].
- Under the Th1 cytokine IFN-γ stimulation, thyrocytes participate to the induction and
perpetuation of inﬂammation by releasing CXCL11; PPAR-γ inhibited this eﬀect [64].
- PPAR-α activation had an inhibitory role on CXCL11 secretion by thyroid cells [38,66].
CCL2 Diﬀerent expression patterns of chemokines in the various thyroid
diseases [63].
CCL5 Diﬀerent expression patterns of chemokines in the various thyroid
diseases [63].
IL-37 IL-37 mRNA levels were increased in GD patients with respect to
patients with inactive disease, or healthy controls [69].
In PBMCs of GD, IL-37 inhibited the production of IL-6, IL-17 and TNF-α [69].
IL-21 An increased serum concentration of IL-21 in untreated GD and HT
patients was present [70].
IL-21 could take part in the pathogenesis of the disease, as the expression of IL-21 and IL-21R
was up-regulated in PBMCs from GD patients [70].
CCL21 Clinical correlation between GD and plasma CCL21 [71].
IL-23 IL-23A gene could be a genetic risk marker in Han Chinese
population [72].
IL-6 A signiﬁcant association between the IL6 -174 G/C polymorphism
and the risk for GD [73].
TNF-α The promoter SNP rs1800629 within the TNF-α gene is associated
with increased risk for developing GD [74].
S.M. Ferrari, et al. Journal of Clinical & Translational Endocrinology 16 (2019) 100196
3
with MMI. Similar chemokines levels were measured in newly diag-
nosed hyperthyroid GD (not treated), vs. untreated patients with re-
lapsed hyperthyroidism. In conclusion the serum chemokines levels
were associated with the active phase of GD (newly diagnosed and
relapsing) and their decrease in treated patients with GD may be related
to the immunomodulatory eﬀects of MMI [67].
A further study investigated about the relationship between the
pathogenesis of AITD and functional polymorphisms in genes encoding
some chemokines [68]. This study genotyped the following poly-
morphisms: IL8 −251 T/A, Monocyte Chemoattractant Protein1
(MCP1)-2518G/A, Regulated upon Activation, Normal T cell Expressed
and presumably Secreted (RANTES) - 403G/A, −28C/G, MIG
rs2276886G/A, IP10 −1596C/T and IL16 −295 T/C. The study en-
rolled: 131 HT patients [of whom 54 who developed moderate to severe
hypothyroidism before 50 years of age and were treated daily with
thyroxine (severe HT) and 46 untreated euthyroid patients with HT,
who were over 50 years of age (mild HT)]; 149 GD patients, of whom
53 with GD in remission, 59 who had been treated with MMI for at least
ﬁve years and were still positive for anti-thyrotropin receptor antibody
(TRAb) (intractable GD); 99 healthy controls. In AITD patients MIG
rs2276886 A allele and IL8 -251TT genotype were more frequent; un-
like the RANTES -403AA and -28GG genotypes which were less fre-
quent. MIG rs2276886 AG genotype was less common in patients with
intractable GD, while the MCP1 -2518GG genotype was more frequent
in HT patients [68]. It’s interesting that in GD patients with -28CG and
GG genotypes the age at onset was higher in comparison to GD patients
having RANTES - 28CC genotype. This study ﬁrstly reported the asso-
ciation between the intractability of GD and the MIG rs2276886 AG
genotype [68].
Other Cytokines/Chemokines (Table 1)
IL-37
The anti-inﬂammatory cytokine IL-37 belongs to the IL-1 family,
and it is able to reduce local and systemic inﬂammation. Its role in GD
patients is still unclear [69]. A study evaluated the expression of IL-37,
IL-6, IL-17 and TNF-α mRNA in peripheral blood mononuclear cells
(PBMCs) in 40 GD patients, and the serum levels of IL-37, IL-6, IL-17
and TNF-α. It was shown that IL-37, IL-6, IL-17 and TNF-α both in
serum and PBMCs were signiﬁcantly higher in GD patients in compar-
ison to control subjects. Circulating IL-37 levels were strictly correlated
with IL-17, IL-6, TNF-α, TSH, TRAb, free T3 (FT3) and free T4 (FT4). In
the active phase of GD, IL-37 mRNA and serum protein levels were
increased with respect to those in patients with inactive disease or
healthy controls. In PBMCs in GD, IL-37 repressed the production of IL-
6, IL-17 and TNF-α. These data suggested that IL-37 inhibits the pro-
duction of proinﬂammatory cytokines in GD, having a protective role
against inﬂammation. For this reason, IL-37 could be considered as a
new research target for the pathogenesis and therapy of GD [69].
IL-21
Another study evaluated the mRNA and protein expression of in-
ﬂammatory cytokines of in vitro PBMCs after the stimulation with re-
combinant human IL-21 (rhIL-21), to investigate the role of IL-21/IL-21
receptor (IL-21R) in the pathogenesis of AITD [70]. Serum IL-21 levels
were higher in not treated GD and HT patients, and in PBMCs in HT, IL-
21+CD3+CD8− T cells were signiﬁcantly higher in comparison to
controls. The IL-21 mRNA in PBMCs was elevated in GD and HT pa-
tients, and a strong increase of IL-21 and IL-21R mRNA in thyroid tis-
sues of HT patients was reported. The expression of IL-21R protein in
HT thyroid cells and lymphocytes was shown by immunohistochemical
staining. Cultured PBMCs from GD patients, in presence of rhIL-21,
stimulated high IL-17A levels but reduced IL-4 production, whilst from
HT patients, in presence of rhIL-21, stimulated an increased production
of IFN-γ. These results showed that in AITD, IL-21 could take part in the
pathogenesis of the disease, as the expression of IL-21 and IL-21R was
up-regulated, increasing an abnormal immune cascade [70].
CCL21
Another paper evaluated the relationship between CC-chemokine
ligand 21 (CCL21) and GD development and the role of osteopontin
(OPN) in the regulation of CCL21 production [71]. In GD, CCL21 has an
important role in the circulation of CC-chemokine receptor 7 (CCR7)-
expressing cells, while OPN stimulates the production of proin-
ﬂammatory cytokines and chemokines, by NF-kB and MAPK signaling
pathways. Fourty newly diagnosed GD without previous treatment, 12
TRAb-negative GD patients, 15 euthyroid GD patients, and 25 healthy
controls were enrolled. It has been shown that plasma CCL21 levels
(determined in plasma and culture supernatants by enzyme-linked
immunoassay) were higher in GD patients and normalized in TRAb-
negative GD patients. Furthermore, CCL21 correlated with TRAb and
plasma OPN. Moreover, recombinant OPN raised the expression of
CCL21 time- and dose-dependently. The reported results suggested a
clinical correlation between GD and plasma CCL21, and that CCL21
could be considered as a new marker in GD and a possible target for
TRAb-positive GD therapy [71].
IL-23
The genetic association between rs11171806 (IL-23A gene poly-
morphism) and susceptibility to GD was investigated by 2 independent
Chinese cohorts [72]. The Shanghai cohort included 712 unrelated GD
patients and 705 controls, and the replication cohort from Xiamen Is-
land consisted of 433 GD patients and 410 controls. Serum IL-23 levels
were signiﬁcantly higher in GD patients than in healthy subjects. Fur-
thermore, in the subgroup analysis, higher concentrations of IL-23 were
reported in the female gender and in patients of older age (≥40 years).
It was also conducted an association study with the IL-23 gene poly-
morphism rs11171806. In Shanghai cohorts, the frequencies of
rs11171806 alleles were markedly diﬀerent between GD patients (G
95.7% and A 4.3%) and healthy controls (G 97.7% and A 2.3%)
[P=2.6×10−3, OR=1.93 (95% CI: 1.25–2.97)], and in Xiamen co-
horts, the proportion of individuals carrying the A allele of rs11171806
was high both in GD patients and in controls, in a similar manner [GD
vs. control, 4.8% vs. 4.3%, OR=2.15 (95% CI: 1.23–3.79),
Pallele= 6.3× 10−3]. These data indicated that in GD the IL-23A gene
could be a genetic risk marker in Han Chinese population [72].
IL-6
The association between IL-6 -174 G/C polymorphism and GD have
been investigated by various studies, with discordant results. A meta-
analysis was conducted to evaluate such association, and included 4
case-control studies with 554 GD cases and 1201 healthy controls [73].
In the combined analysis, a signiﬁcant association between the IL-6
-174 G/C polymorphism and the risk for GD in dominant model
(OR=1.39, 95% CI: 1.07–1.80), recessive model (OR=2.75, 95% CI:
1.01–7.55) and homozygote contrast model (OR=3.25, 95% CI:
1.1–9.58) was shown [73].
TNF-α
Another meta-analysis was performed on rs1800629 and rs361525
in the TNF-α gene from all the eligible case–control studies to in-
vestigate whether TNF-α is able to inﬂuence the susceptibility to GD
[74]. Ten case–control studies involving 2790 GD patients and 3472
healthy controls were included. A signiﬁcant association was shown
between the rs1800629 polymorphism and GD in the homozygous
model (AA compared with GG: OR=1.97, 95% CI=1.27–3.06,
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P=0.002) and recessive model (AA compared with GA+GG:
OR=1.62, 95% CI=1.04–2.50, P=0.03). GD susceptibility was sig-
niﬁcantly detected in European population in all genetic models after
ethnicity stratiﬁcation, while no signiﬁcant association existed in Asian
population. The single-nucleotide polymorphism (SNP) rs361525 did
not show a signiﬁcant association with GD in any genetic model before
and after ethnicity stratiﬁcation. The results suggested that only the
promoter SNP rs1800629 within the TNF-α gene is associated with
increased risk for developing GD, in particular in European population
[74].
Conclusion
Th1-dependent chemokines and their receptor, CXCR3, contribute
to the pathogenesis of GD, and are secreted by thyrocytes upon the
stimulation with IFN-γ. In tissues, recruited Th1 lymphocytes may be
responsible for enhanced IFN-γ and TNF-α production, which in turn
stimulates Th1 chemokines secretion from these cells, leading to an
ampliﬁcation feedback loop, that can further perpetuate the auto-
immune process.
Chemokines produced in the inﬂamed tissues enter into the circu-
lation, and high levels of IFN-γ induced chemokines present in per-
ipheral ﬂuids can be considered a marker for the host immune response.
The determination of high levels of Th1 chemokines in peripheral li-
quids can be considered as a marker of a Th1 orientated immune re-
sponse, and circulating levels of these chemokines are associated with
the active phase of GD in both newly diagnosed, and relapsing hy-
perthyroid patients.
MMI reduces the secretion of Th1 chemokines by isolated thyr-
ocytes, and serum levels, and promotes a transition from Th1 to Th2
dominance in patients in GD active phase. PPAR-γ and PPAR-α acti-
vators are able to modulate the IFN-γ induced Th1 chemokines secre-
tion in vitro, in GD thyrocytes.
Other cytokines, such as IL-37, IL-21, CCL21 and IL-23A, have been
investigated in order to evaluate their role in the pathogenesis of GD.
Additional researches are needed to evaluate the interactions be-
tween chemokines and cytokines in the pathogenesis of GD, and to
investigate whether Th1 chemokines could be considered a novel
therapeutic target in this autoimmune disorder.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jcte.2019.100196.
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